MultiCenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ATX-101 (Sodium Deoxycholate Injection) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area

Trial Profile

MultiCenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ATX-101 (Sodium Deoxycholate Injection) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Feb 2018

At a glance

  • Drugs Deoxycholic acid (Primary)
  • Indications Subcutaneous fat disorders
  • Focus Registrational; Therapeutic Use
  • Acronyms REFINE-2
  • Sponsors Kythera Biopharmaceuticals
  • Most Recent Events

    • 16 Feb 2018 According to an Allergan media release, follow up data from REFINE Trials will be presented at the 2018 American Academy of Dermatology (AAD) Annual Meeting.
    • 15 Jul 2016 Results published in the Journal of the American Academy of Dermatology (2016).
    • 01 Jul 2016 According to an Allergan media release, the company has received positive opinion from the Swedish Medical Products Agency (MPA) for deoxycholic acid (BELKYRA) through European decentralised procedure for the treatment of subdermal fullness.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top